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Cognitive impairment is highly prevalent in patients with schizophrenia and schizoaffective disorder. Many interventions have
been developed to treat cognitive deficit, since it has a strong impact on functional outcome; however, there are no integrated
interventions targeting multiple neuro- and social-cognitive domains with a particular focus on the generalization of the effects of
therapy on the functional outcome. Recently, a group of experts has developed a cognitive remediation group therapy approach
called IntegratedNeurocognitiveTherapy (INT), which includes exercises to improve theMATRICS (Measurement and Treatment
Research to Improve Cognition in Schizophrenia) neuro- and social-cognitive domains. This systematic review and meta-analysis
aimed to assess the efficacy of this approach. We conducted a search of PubMed, Scopus, Web of Science, and PsycINFO to select
primary studies evaluating INT in schizophrenic and schizoaffective patients.The primary outcomes of the meta-analysis included
negative and positive symptoms and global functioning. Two randomized controlled trials met inclusion criteria. A total of 217
participants were included. Based on the results from the Positive and Negative Syndrome Scale (PANSS), a significant pooled
effect size was observed for negative symptoms, which demonstrated not only an improvement in the patients treated immediately
after therapy but also a permanence of positive results at a 9–12-month follow-up. On the other hand, no significant effect size was
observed for positive symptoms. In addition, a significant pooled effect size was found forGlobal Assessment of Functioning (GAF),
which shows how INT’s integrated approach has lasting positive implications on patients’ functional outcome. We concluded that
INT might be an effective treatment for negative symptoms and global functioning in patients with schizophrenia, compared to
treatment as usual (TAU).
1. Introduction
Cognitive deficits are one of the most important features in
schizophreniawith significant consequences on patients’ psy-
chosocial functioning [1]. According to some studies, about
98% of schizophrenic patients have an impairment in a wide
range of cognitive functions [2], including working memory,
attention, processing speed, visual and verbal learning with
substantial deficit in reasoning, planning, abstract thinking,
and problem solving [3].
Two recent meta-analyses demonstrate that a minor
cognitive impairment is present at the onset of the dis-
ease. The authors of these studies reported the values of
premorbid IQ (Intelligence Quotient) in subjects who later
developed schizophrenia, showing that years before the onset
of psychotic symptoms, individuals with schizophrenia, as
a group, demonstrated mean IQ scores approximately one-
half of a standard deviation below that of healthy comparison
subjects. [4, 5].
In support of the observation that social and occupational
impairment in schizophrenic patients is strongly correlated
with neurocognitive deficits, there has been an increas-
ing interest in the development of new pharmacological
agents to improve cognition, and consequently an interest in
determining which cognitive domains should be represented
in a battery of standardized neuropsychological tests, in
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order to evaluate the efficacy of pharmacological treatments.
From these considerations, the MATRICS project (Mea-
surement and Treatment Research to Improve Cognition in
Schizophrenia) starts [6].
In order to develop a standardized cognitive battery to
foster the evaluation of cognitive enhancement interventions,
the group of experts of the MATRICS project identified
the major separable cognitive impairments in schizophrenia.
Summing up the data of a large number of studies, these
authors have identified the cognitive areas that are altered
in patients by dividing them into seven separate cognitive
domains that were replicable across studies: speed of process-
ing, attention/vigilance, working memory, verbal learning
and memory, visual learning and memory, reasoning and
problem solving, and social cognition [7].
However, to date, it has been seen that antipsychotic
drugs have an effect on the main symptoms of the disease
but not on these cognitive domains, which explains the
increasingly widespread use of cognitive remediation for
schizophrenia [8]. Cognitive remediation techniques are
defined as interventions based on behavioural training that
aims to improve cognitive processes in a long-lasting and
generalizable way [9]. These interventions can be classified
according to two models: compensatory and reparative.
Compensatory interventions try to bypass the deficit and
compensate for it by relying on intact cognitive skills and
environmental resources, promoting an adaptation of the
context in which the patient lives and an adaptation of his
behaviour to the specific situation, while restorative inter-
ventions try to correct and improve the deficit by drill and
practice exercises. The restorative techniques are based on
neuroscientific knowledge according to which the neuronal
processes compromised can be repaired through repeated
exercise, which leads to a restoration of those neuroanatom-
ical connections linked to neuropsychological abilities. This
particularly concerns the white matter pathways which,
as known through many studies about imaging and MR
techniques in schizophrenia, play an important role in the
neuropathology of schizophrenia, and are likely related to
clinical symptoms observed in this disorder [10]. We must
also remember that the restorative model may utilize either
a bottom-up (cognitive recovery of elementary skills to get to
the most complex ones) or a top-down (use of complex skills
to improve indirectly the simplest ones) approach [11].
Over the last few years, different structured protocols of
cognitive remediation have been proposed and elaborated,
which can be distinguished by the mode of application (indi-
vidual or group; computerized or paper and pen; constant
presence of the therapist) or by whether they are primarily
based on repeated execution of specific tasks, or on the
development and learning of new strategies [9].
Some recent meta-analyses have shown that cognitive
remediation interventions have positive effects not only on
cognitive performance, but also on psychosocial functioning
and, to a small degree, on symptoms that tend to disappear at
the first follow-up [12, 13].
Studies reported that social cognition (comprising emo-
tional perception and social knowledge), is related to both
neurocognition and functional outcome [14]. Although it
would suggest that an integrated treatment of neuro- and
social cognition may produce better generalization effects on
functional outcome than neuro- or social-cognitive therapy
alone, only a few interventions that combine the rehabilita-
tion of both cognitions have been developed.
Furthermore, as there is no evidence that boosting one
cognitive domain might improve functional outcome more
than another [15], an approach targeting multiple cognitive
domains may be of benefit for most schizophrenia patients.
Nevertheless, none of the contemporary approaches inte-
grates all cognitive domains identified by the MATRICS
project experts. [16].
Only recently did a group of experts from the Univer-
sity of Bern develop such an approach—called Integrated
Neurocognitive Therapy (INT)—which combines both neu-
rocognition and social cognition by developing specific
interventions for each MATRICS domain. In this way, based
on the results of current meta-analyses [12, 13, 17], a sig-
nificant improvement in cognitive domains, symptoms, and
functional outcome is assumed [16, 18].
This recent intervention is an evolution of the previous
cognitive remedy intervention called Integrated Psycholog-
ical Therapy (IPT) that aimed to improve specific cognitive
functions and the acquisition of social skills through five sub-
programs: cognitive differentiation, social perception, verbal
communication, social skills, and interpersonal problem-
solving [19].
The INT is composed of four modules, each of which
focuses on different cognitive domains and on social cog-
nition: Module A takes into account the processing speed,
attention and perception of emotions; Module B concerns
verbal and visual learning and memory, social perception
and theory of mind; Module C is about reasoning, problem
solving, and “social schemes”; and Module D trains working
memory and the ability to attribute appropriate meanings.
Some exercises within the four modules use a computer,
particularly the Cogpack computer program [20].
From the preliminary research, we found two articles [16,
18] that tested the effectiveness of INT based on randomized
control trials. Then, we did a systematic literature review and
conducted a meta-analysis to quantify the improvement of
patients following therapy and the permanence of positive
effects at follow-up after about one year.
2. Material and Methods
2.1. Search Strategy. We searched four electronic databas-
es—PubMed, Web of Science, Scopus and PsycINFO— from
inception to May 2018. The search terms that we used were
“Integrated Neurocognitive Therapy”, “Schizophrenia”, and
“Randomized controlled trial”. No language restrictions were
imposed and we applied the following inclusion criteria: (1)
randomized controlled trial that (2) evaluated INT versus
TAU (treatment as usual) in (3) adult patients with diagnosis
of schizophrenia or schizoaffective disorder.
2.2. Studies Selection and Quality Assessment. Two authors
independently researched the articles using the search terms
and independently screened titles and abstracts according to
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Figure 1: Flow-chart.
the eligibility criteria to select relevant studies. The quality
of the included studies was assessed by using Cochrane
Collaboration’s tool for assessing risk of bias by RevMan [21]
and by extracting PEDro (Physiotherapy Evidence Database)
scores from the PEDro website. Each score on the PEDro
website is generated by two accredited raters scoring the trial;
any discrepancies in rating are resolved by a third accredited
rater (https://www.pedro.org.au/).
2.3. Statistical Analysis. We performed a meta-analysis using
Review Manager software (RevMan, the Cochrane Collabo-
ration).The mean difference (MD) was used as the effect size
for continuous outcomes. A fixed-effect model was used, as
we expected a fixed effect-size from the studies. The overall
effect sizes were calculated based on the pooled propor-
tions and 95% confidence intervals (CIs). The differences
between the studies were calculated through the overall
effect size (Z), with a statistical significance threshold of p
<0.05. The data used for statistical analysis were divided
according to two points in time: first, we considered the
posttreatment results after 15 weeks and, then, the results
obtained at a follow-up that included a range of 9-12
months.
2.4. Outcome Measures. The primary outcomes of inter-
est included negative and positive symptoms measured by
PANSS (positive and negative syndrome scales) and global
functioning assessed by GAF (Global Assessment of Func-
tioning Scale). We collected both the posttreatment outcome
at 15 weeks and the follow-up outcome creating a range from
9 to 12 months.
3. Results
3.1. Search Results. The study selection process is dia-
grammed in Figure 1. A total of 44 recordswere identified and
screened through the initial search strategy, and a total of 42
recordswere excluded based on irrelevant titles and abstracts.
Two RCTs (randomized controlled trials) met the eligibility
criteria.
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Table 1: Characteristics of the studies.
Mean Mueller 2015N=156
Mueller 2017
N=61
Age 34.2 35.6
Gender (N male) 108 47
IQ mean 103.9 101.6
Duration of Illness (years) 10 10.8
Number of hospitalizations 4.1 4.3
Chlorpromazine equivalent doses 439.1 406
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Figure 2: Quality appraisal. + (green), low risk of bias; ? (yellow), unclear risk of bias; − (red), high risk of bias.
3.2. Characteristics of Included Studies. A summary of studies
characteristics is shown in Table 1. The two studies were
published from 2015–2017 and included 217 participants: 155
of them were male and 62 were female. The mean age across
all participants was 34.9 years (age range: 18-50). The intelli-
gence quotient (IQ) mean, assessed by the ReducedWechsler
Intelligence Test (WIP), was 102.7; the mean duration of
illness was 10.4, while the number of hospitalizations was 4.2.
The chlorpromazine equivalent doses mean was 422.5.
The studies were from Switzerland, and in both of them,
the modalities of intervention were the same: 30 biweekly
sessions of INT, with each session lasting 90 minutes. Like-
wise, each RCT compared the intervention groups to the
TAU groups; TAU is defined as standard care which includes
a broad array of intervention used in clinical practice for
schizophrenic patients.
3.2.1. Trial Quality. The Cochrane collaboration’s tool for
assessing risk of bias was used to assess risk of bias of each
study (Figure 2). Both studies were assigned high risk in
blinding of participants and personnel (performance bias)
due to the nature of treatment; on the other hand, risk of all
other bias was low, apart from selection bias risk, which was
unclear in Mueller 2017 trial because of a missing adequate
description of randomisation.
We also used the PEDro scores to assess the quality of
included studies (Table 2). According to the PEDro criteria,
the quality of the studies can be classified as three ranges: low
quality (scores 0-3), medium quality (scores 4-7), and high
quality (scores 8-10). The score of 10 reflects the best qual-
ity.
The score of our papers was 8, due to missing blind
participants and therapists. In both Mueller’s studies, the
dropout rate was <15% at each point in time: for the 15-week
therapy phase and 10.2% dropped out in the 2015 study, while
9.8% dropped out for the 2017 one.
For the 9-12-month follow-up phase, 13.6% dropped out
in the 2015 study, while 12.7% dropped out for the 2017 one.
Both RCTs were rated as high-quality studies. The quality
assessments were initially completed by a single reviewer and
then checked for accuracy by one other reviewer.
3.3. Meta-Analysis of Primary Outcomes. Data from the
PANSS Negative and Positive Syndrome Scale and the Global
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Table 2: Pedro scores for included papers (n=2) extracted from website www.pedro.org.au.
Mueller 2015 Mueller 2017
Eligibility Criteria YES YES
Random allocation YES YES
Concealed allocation YES YES
Groups similar at baseline YES YES
Participant blinding NO NO
Therapist blinding NO NO
Assessor Blinding YES YES
<15% dropouts YES YES
Intention to treat analysis YES YES
Between-group difference reported YES YES
Point estimate and variability reported YES YES
Total (0-10) 8 8
Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 4.12 (P < 0.0001)
Mean
14.09
17.5
SD
5.27
4.5
Total
73
24
97
Mean
17.56
19.6
SD
5.38
4.5
Total
67
31
98
Weight
64.8%
35.2%
100.0%
IV, Fixed, 95% CI
-3.47 [-5.24, -1.70]
-2.10 [-4.50, 0.30]
-2.99 [-4.41, -1.57]
INT TAU Mean Difference
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
+ + – + + + +
? + – + + + +
Risk of Bias
A B C D E F G
Mean Difference
IV, Fixed, 95% CI
−20 −10 0 10 20
Favours INT Favours TAU
Heterogeneity: ChＣ2 = 0.81, df = 1 (P = 0.37); ）2 = 0%
(a) Impact of Integrated Neurocognitive Therapy (INT) on negative symptoms assessed by PANSS negative symptoms after 15 weeks
Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 2.96 (P = 0.003)
Mean
13.68
16.4
SD
5.04
4.9
Total
64
20
84
Mean
16.29
18.6
SD
6.12
5
Total
57
29
86
Weight
66.2%
33.8%
100.0%
IV, Fixed, 95% CI
-2.61 [-4.62, -0.60]
-2.20 [-5.01, 0.61]
-2.47 [-4.11, -0.83]
Experimental Control Mean Difference
Risk of bias legend
+ + – + + + +
? + – + + + +
Risk of Bias
A B C D E F G
Mean Difference
IV, Fixed, 95% CI
−20 −10 0 10 20
Favours [INT] Favours [TAU]
Heterogeneity: ChＣ2 = 0.05, df = 1 (P = 0.82); ）2 = 0%
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
(b) Impact of Integrated Neurocognitive Therapy (INT) on negative symptoms assessed by PANSS negative symptoms at 9-12 month follow up
Figure 3
Assessment of Functioning Scale were included in the meta-
analysis.
3.4. Effectiveness of INT on Negative Symptoms Assessed by
PANSS. Based on the results from PANSS negative symp-
toms, a significant pooled effect size was observed after
15 weeks (MD -2.99, 95%CI -4.41 to -1.57, and P<0.0001;
Figure 3(a)) and at 9-12-month follow-up (MD -2.47, 95%CI
-4.11 to -0.83, and P=0.003; Figure 3(b)), with no evidence of
statistical heterogeneity (I2=0%).
Since in this scale, lower scores indicate more improve-
ments, INT produced a reduction in negative symptoms,
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Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 1.88 (P = 0.06)
Mean
13.13
14.6
SD
4.14
3.2
Total
73
24
97
Mean
14.79
15.2
SD
5.7
4.8
Total
67
31
98
Weight
61.9%
38.1%
100.0%
IV, Fixed, 95% CI
-1.66 [-3.32, 0.00]
-0.60 [-2.72, 1.52]
-1.26 [-2.56, 0.05]
INT TAU Mean Difference
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
+ + – + + + +
? + – + + + +
Risk of Bias
A B C D E F G
Mean Difference
IV, Fixed, 95% CI
0 10 20
Favours INT Favours TAU
Heterogeneity: ChＣ2 = 0.59, df = 1 (P = 0.44); ）2 = 0%
(a) Impact of Integrated Neurocognitive Therapy (INT) on positive symptoms assessed by PANSS negative symptoms after 15 weeks
Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 1.43 (P = 0.15)
Mean
12.82
15.2
SD
4.67
4.8
Total
64
20
84
Mean
14.07
15.4
SD
4.06
4
Total
57
29
86
Weight
73.0%
27.0%
100.0%
IV, Fixed, 95% CI
-1.25 [-2.81, 0.31]
-0.20 [-2.76, 2.36]
-0.97 [-2.30, 0.36]
Experimental Control Mean Difference
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
+ + – + + + +
? + – + + + +
Risk of Bias
A B C D E F G
Mean Difference
IV, Fixed, 95% CI
0 10 20
Favours [INT] Favours [TAU]
Heterogeneity: ChＣ2 = 0.47, df = 1 (P = 0.49); ）2 = 0%
−20 −10
(b) Impact of Integrated Neurocognitive Therapy (INT) on positive symptoms assessed by PANSS negative symptoms at 9-12-month follow-up
Figure 4
which was maintained at the follow up, as shown in Figures
3(a) and 3(b).
3.5. Effectiveness of INT on Positive Symptoms Assessed by
PANSS. No significant pooled effect sizes were found for
PANSS Positive symptoms after 15 weeks (MD -1.26, 95%CI
-2.56 to 0.05, and P=0.06; Figure 4(a)), as well as 9-12 month-
follow-up (MD -0.97, 95%CI -2.30 to 0.36, and P=0.15;
Figure 5(a)) with no evidence of statistical heterogeneity
(I2=0%).
3.6. Effectiveness of INT on Functional Outcome Assessed by
Global Assessment of Functioning Scale (GAF). A significant
pooled effect size was observed for GAF after 15 weeks
(MD 2.38, 95%CI 0.02 to 4.74, and P=0.05; Figure 5(a)),
and at 9-12-month follow-up (MD 4.58, 95%CI 2.03 to 7.12,
and P=0.0004; Figure 5(b)) with no evidence of statistical
heterogeneity (I2=0%).
4. Discussion
Although there are many studies on various cognitive reme-
diation approaches, there are only two trials conducted
specifically on INT which tested its efficacy. Both the RCTs
we found demonstrated the improvement of the patients in
different deficit areas, so we summarized the data to integrate
the results; we hoped to obtain a single quantitative estimate
index that would allow us to draw stronger conclusions than
those drawn on the basis of each single study.
It would be important to have access to a greater
amount of data to conduct a meta-analysis and, therefore, a
more exhaustive synthesis. This would allow the creation of
stronger evidence than that deriving from the clinical stud-
ies, which is important considering the impact this type
of intervention could have on the functional recovery of
schizophrenic patients.
In this systematic review and meta-analysis, we iden-
tified two eligible studies assessing the effect of INT on
schizophrenic or schizoaffective patients. From the meta-
analysis, we found that INT had a significant impact upon
negative symptoms and functional outcome, compared to
TAU, as demonstrated by improved scores in both assess-
ment scale used. However, no significant improvement was
observed in positive symptoms.
INT is a new cognitive remediation group approach.
It incorporates all 11 neuro- and social cognitive domains
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Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 1.97 (P = 0.05)
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52.6
48.3
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8.3
7.9
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24
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Weight
69.5%
30.5%
100.0%
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INT TAU Mean Difference
Risk of bias legend
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(G) Other bias
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(a) Impact of Integrated Neurocognitive Therapy (INT) on functional outcome assessed by Global Assessment of Functioning scale (GAF) after 15 weeks
Study or Subgroup
Mueller 2015
Mueller 2017
Total (95% CI)
Test for overall effect: Z = 3.52 (P = 0.0004)
Mean
55.41
51.3
SD
7.33
8.2
Total
64
20
84
Mean
50.72
47
SD
9.42
8.3
Total
57
29
86
Weight
70.5%
29.5%
100.0%
IV, Fixed, 95% CI
4.69 [1.66, 7.72]
4.30 [-0.39, 8.99]
4.58 [2.03, 7.12]
Experimental Control Mean Difference
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
+ + – + + + +
? + – + + + +
Risk of Bias
A B C D E F G
Mean Difference
IV, Fixed, 95% CI
0 50 100
Favours [TAU] Favours [INT]
−100 −50
Heterogeneity: ChＣ2 = 0.02, df = 1 (P = 0.89); ）2 = 0%
(b) Impact of Integrated Neurocognitive Therapy (INT) on functional outcome assessed by Global Assessment of Functioning scale (GAF) at 9-12-month
follow-up
Figure 5
defined by National Institute of Mental Health-Measurement
and Treatment Research to Improve Cognitions in Schizo-
phrenia (NIMH-MATRICS) into four therapymodules. Each
module starts with interventions on neurocognitive domains
and is followed by interventions on social cognition [18].
The meta-analysis provides evidence that INT may be
effective in treating schizophrenic patients’ cognitive impair-
ment. It could decrease negative symptoms, while pharmaco-
logical treatments have shown limited success for alleviating
them. On the other hand, the most important finding of our
study was that INT produced robust and durable generaliza-
tion effects on functional outcome, as assessed by the GAF,
which even increased over time [18].
4.1. Study Limits. This study has several limitations. First, due
to the limited number of existing RCTs on INT, this meta-
analysis was based only on data extracted from the two RCTs.
Second, even if other outcomes assessed in the two RCTs
could be comparable, in one article, there were some scales
including standardized scores, so the comparison could not
be realized.
Due to the limited number of included studies, these
results should be confirmed by further large-scale RCTs
which focus on INT’s effects on schizophrenic patients.
4.2. Conclusions. This study was conducted by a research
group composed of medical doctors and rehabilitation pro-
fessionals from the Sapienza University of Rome and from
the Rehabilitation &OutcomeMeasure Assessment (ROMA)
association. In the last few years, the ROMA association has
dealt with the validation of many outcome measures in Italy.
[22–37]
In summary, despite the limitations, our results suggest
that INT is a feasible and effective approach; it has the
potential to improve neuro- and social cognition and, in a
lasting way, to influence positively functional outcome in
schizophrenia outpatients. However, the durability of the
effects on the reduction of positive symptoms was not found.
Given the current scarcity of RTCs, further studies are
needed to compare between different patient populations and
to produce stronger evidence in this specific rehabilitative
setting.
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